In previous studies of eyes receiving anti-VEGF therapies based on PRN protocols for age-related macular degeneration (AMD) and branch retinal vein occlusion (BRVO), eyes with greater foveal thickness (FT) fluctuation (FTF) showed poorer final VA values and more severe foveal damage than those with smaller fluctuations.17 The gene discussed is VEGFA; the disease is age-related macular degeneration.